Jasper Therapeutics (JSPR) Competitors $2.72 -0.04 (-1.45%) Closing price 04:00 PM EasternExtended Trading$2.72 0.00 (0.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. MDWD, AARD, ENTA, TVGN, CGTX, BIOA, CYBN, DERM, ACTU, and FTLFShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include MediWound (MDWD), Aardvark Therapeutics (AARD), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Cognition Therapeutics (CGTX), BioAge Labs (BIOA), Cybin (CYBN), Journey Medical (DERM), Actuate Therapeutics (ACTU), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors MediWound Aardvark Therapeutics Enanta Pharmaceuticals Tevogen Bio Cognition Therapeutics BioAge Labs Cybin Journey Medical Actuate Therapeutics FitLife Brands MediWound (NASDAQ:MDWD) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Which has more risk & volatility, MDWD or JSPR? MediWound has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Is MDWD or JSPR more profitable? Jasper Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -142.18%. MediWound's return on equity of -96.71% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MediWound-142.18% -96.71% -39.73% Jasper Therapeutics N/A -172.28%-128.34% Does the media refer more to MDWD or JSPR? In the previous week, MediWound had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for MediWound and 0 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.70 beat MediWound's score of 0.35 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MediWound Neutral Jasper Therapeutics Positive Which has higher earnings and valuation, MDWD or JSPR? MediWound has higher revenue and earnings than Jasper Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M8.86-$30.22M-$2.64-6.28Jasper TherapeuticsN/AN/A-$71.27M-$6.01-0.45 Do insiders & institutionals hold more shares of MDWD or JSPR? 46.8% of MediWound shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer MDWD or JSPR? MediWound currently has a consensus price target of $32.25, suggesting a potential upside of 94.63%. Jasper Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 956.99%. Given Jasper Therapeutics' higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryMediWound beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.51M$3.12B$5.77B$9.77BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.4521.1082.3726.60Price / SalesN/A405.47535.29174.93Price / CashN/A43.5325.7028.92Price / Book1.888.1310.646.56Net Income-$71.27M-$53.35M$3.28B$266.04M7 Day Performance-6.21%0.45%-0.08%-0.58%1 Month Performance-5.56%9.94%10.36%6.24%1 Year Performance-85.82%11.73%49.00%22.21% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.8063 of 5 stars$2.72-1.4%$28.75+957.0%-87.3%$45.51MN/A-0.4520MDWDMediWound1.6845 of 5 stars$16.70-0.7%$32.25+93.1%-9.7%$180.49M$20.22M-6.3380News CoverageAARDAardvark TherapeuticsN/A$8.30-2.2%$32.60+292.8%N/A$180.08MN/A0.0018ENTAEnanta Pharmaceuticals3.7863 of 5 stars$8.40-3.3%$21.67+157.9%-30.1%$179.57M$67.64M-1.94160News CoveragePositive NewsAnalyst ForecastTVGNTevogen Bio3.3838 of 5 stars$0.91+0.8%$10.00+998.9%+70.5%$179MN/A0.003Short Interest ↑CGTXCognition Therapeutics1.7309 of 5 stars$2.43-2.0%$2.83+16.6%+241.6%$178.66MN/A-3.6320News CoverageBIOABioAge LabsN/A$4.93+2.7%N/AN/A$176.74MN/A0.00N/APositive NewsCYBNCybin1.8801 of 5 stars$7.48-2.1%$85.00+1,036.4%N/A$176.45MN/A-1.7150News CoverageGap UpDERMJourney Medical1.8488 of 5 stars$7.21-0.8%$12.17+68.7%+43.0%$175.77M$56.13M-18.9790ACTUActuate TherapeuticsN/A$8.44+2.7%$20.33+140.9%+8.1%$175.09MN/A0.0010FTLFFitLife Brands3.8709 of 5 stars$18.62-0.3%$22.00+18.2%+8.6%$174.86M$64.47M22.1720Positive News Related Companies and Tools Related Companies MediWound Alternatives Aardvark Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Tevogen Bio Alternatives Cognition Therapeutics Alternatives BioAge Labs Alternatives Cybin Alternatives Journey Medical Alternatives Actuate Therapeutics Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThe Orphaned Well Crisis Hidden Across AmericaAcross the U.S., millions of abandoned oil and gas wells are leaking methane into the air — a costly and dange...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts